Vanguard Global Advisers’s AEON Biopharma AEON Stock Holding History

Vanguard Global Advisers’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-102	Closed	-$100	–	3642
2026 Q1	$100	Buy	+102	New	+$114	﹤0.01%	3676

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's AEON Position: Q2 2026 in Review

Vanguard Global Advisers sold out of AEON Biopharma (AEON) in Q2 2026, closing a stake of 102 shares — an estimated $100 sold.

Vanguard Global Advisers first reported a position in AEON in Q1 2026 and held it in 1 quarter. The position peaked at $100 in Q1 2026. 23 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

Vanguard Global Advisers reported no remaining AEON Biopharma position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 102 AEON Biopharma shares in Q2 2026, an estimated $100.
Vanguard Global Advisers first reported a position in AEON Biopharma in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's AEON Biopharma position peaked at $100 in Q1 2026.
23 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.